TY - JOUR
T1 - Vagal stimulation suppresses ischemia-induced myocardial interstitial myoglobin release
AU - Kawada, Toru
AU - Yamazaki, Toji
AU - Akiyama, Tsuyoshi
AU - Kitagawa, Hirotoshi
AU - Shimizu, Shuji
AU - Mizuno, Masaki
AU - Li, Meihua
AU - Sugimachi, Masaru
N1 - Funding Information:
This study was supported by a Health and Labor Sciences Research Grant for Research on Advanced Medical Technology, a Health and Labor Sciences Research Grant for Research on Medical Devices for Analyzing, Supporting and Substituting the Function of the Human Body, and a Health and Labor Sciences Research Grant H18-Iryo-Ippan-023 from the Ministry of Health, Labour and Welfare of Japan.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/9/26
Y1 - 2008/9/26
N2 - Aims: To evaluate vagal stimulation-mediated myocardial protection against ischemia and reperfusion in in vivo ischemic myocardium. Main methods: We measured myocardial interstitial myoglobin levels in the ischemic region using a cardiac microdialysis technique in anesthetized and vagotomized cats. We occluded the left anterior descending coronary artery (LAD) for 60 min and reperfused it for 60 min (VX group, n = 6). The effects of bilateral vagal stimulation (10 V, 5 Hz, 1-ms pulse duration), initiated immediately after LAD occlusion, were examined (VS group, n = 6). To examine the involvement of phosphatidylinositol 3-kinase (PI3K), vagal stimulation was performed after pretreatment with a PI3K inhibitor wortmannin (0.6 mg/kg, i.v.) (VS-W group, n = 6). To examine the contribution of bradycardia, vagal stimulation was performed with fixed-rate ventricular pacing (VS-P group, n = 6). Key findings: The average myoglobin level during the ischemic period was 1170 ± 141 in VX (in ng/ml, mean ± SE), which was significantly attenuated in VS (466 ± 87, P < 0.05) and VS-W (613 ± 124, P < 0.05) but not in VS-P (953 ± 203). Reperfusion increased the myoglobin level to 2500 ± 544 in VX, whereas it was suppressed in VS (824 ± 213, P < 0.05) and VS-W (948 ± 315, P < 0.05) but not in VS-P (1710 ± 253). Significance: Vagal stimulation, initiated immediately after LAD occlusion, attenuated the myocardial injury. Moreover, bradycardia, independent of PI3K pathway, plays a significant role in vagally induced cardioprotection during acute myocardial ischemia.
AB - Aims: To evaluate vagal stimulation-mediated myocardial protection against ischemia and reperfusion in in vivo ischemic myocardium. Main methods: We measured myocardial interstitial myoglobin levels in the ischemic region using a cardiac microdialysis technique in anesthetized and vagotomized cats. We occluded the left anterior descending coronary artery (LAD) for 60 min and reperfused it for 60 min (VX group, n = 6). The effects of bilateral vagal stimulation (10 V, 5 Hz, 1-ms pulse duration), initiated immediately after LAD occlusion, were examined (VS group, n = 6). To examine the involvement of phosphatidylinositol 3-kinase (PI3K), vagal stimulation was performed after pretreatment with a PI3K inhibitor wortmannin (0.6 mg/kg, i.v.) (VS-W group, n = 6). To examine the contribution of bradycardia, vagal stimulation was performed with fixed-rate ventricular pacing (VS-P group, n = 6). Key findings: The average myoglobin level during the ischemic period was 1170 ± 141 in VX (in ng/ml, mean ± SE), which was significantly attenuated in VS (466 ± 87, P < 0.05) and VS-W (613 ± 124, P < 0.05) but not in VS-P (953 ± 203). Reperfusion increased the myoglobin level to 2500 ± 544 in VX, whereas it was suppressed in VS (824 ± 213, P < 0.05) and VS-W (948 ± 315, P < 0.05) but not in VS-P (1710 ± 253). Significance: Vagal stimulation, initiated immediately after LAD occlusion, attenuated the myocardial injury. Moreover, bradycardia, independent of PI3K pathway, plays a significant role in vagally induced cardioprotection during acute myocardial ischemia.
KW - Cardiac microdialysis
KW - Cats
KW - Coronary artery occlusion
UR - http://www.scopus.com/inward/record.url?scp=52049120797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52049120797&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2008.07.013
DO - 10.1016/j.lfs.2008.07.013
M3 - Article
C2 - 18713640
AN - SCOPUS:52049120797
SN - 0024-3205
VL - 83
SP - 490
EP - 495
JO - Life Sciences
JF - Life Sciences
IS - 13-14
ER -